StockWatch
·

India Pesticides Ltd Q2 FY27 Results

IPLQ2 FY27 Results
Filing
Result:Poor· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue228.719.2%59.6%
Total Income231.319.6%60.1%
Expenditure206.588.2%57.4%
PBT24.7319.8%73.7%
Net Profit18.4219.1%72.3%
OPM13.39%0.70pp3.23pp
NPM7.96%0.94pp3.53pp
EPS1.6019.2%72.3%
View full financials

Revenue fell 59.6% YoY and adjusted PAT fell 72.3% YoY with OPM down ~320bps and NPM down ~350bps, a sharp broad-based deterioration in the core chemicals business rather than a one-off hit.

INDIA PESTICIDES LIMITED · Q2 FY-2027 · THE VERDICT

Margin collapse and capex bets: IPL's guidance was already cut — Q2 confirms it

Net profit crashed 72.3% YoY and margins compressed below management's revised targets. The quarter wasn't a miss — it was proof that prior guidance was overstated and has now been reset downward twice in two quarters.

10 Nov 2026 · 6 min read
Reported PAT

₹18.4 Cr

-72.3% YoY

Net margin

8.0%

vs 27% prior

OPM vs target

13.4%

below 14.4% claim & 15–18% prior target

Export orders

₹100 Cr

received; execution begins Q3

India Pesticides' Q2 earnings print is a study in sequential downward revisions. Revenue collapsed 59.6% to ₹228.7 Cr, and net profit fell 72.3% to ₹18.4 Cr—not because the quarter was a surprise, but because management had already reset expectations lower in Q1, and Q2 confirmed that earlier reset was insufficient. The core tension: the company is caught between domestic structural weakness (monsoon deficiency, weak herbicide demand) and a capex bet (Hamirpur expansion, ₹120–135 Cr total) whose returns remain speculative. Export orders provide a lifeline—₹100 Cr just received—but have not yet translated to revenue.

The cascade of guidance cuts

What management promised vs. what it's now saying
MetricQ1 FY27 GuidanceQ2 FY27 NowChange
Revenue growthLower single-digitMaintain last yearCut to defensive (flat-to-negative)
EBITDA margin target15–18%Maintain 14.4%Cut 160–360 bps
Hamirpur FY27 revenue₹50–60 Cr guidance2 of 10 blocks only; implied ₹30–40 CrHalved from ₹70–100 Cr prior
Full-year capex₹100 Cr₹120–135 CrUp 20–35%; returns delayed

Claims vs. what held up on the call

Management's key statements graded
  • "Confident of maintaining EBITDA margin at 14.4%"

  • Reality: Q2 OPM delivered 13.4%, below stated 14.4% and prior 15–18% target

  • "Hamirpur facility progressing on schedule"

  • Reality: Only 2 of 10 blocks operational; 2 more expected early FY28, not H2 FY27

  • "Export orders provide support for outlook" (~₹100 Cr received)

  • Reality: Orders confirmed; execution begins Q3 onwards. Partial execution Q2 (~₹88–89 Cr run-rate implied in H1 ₹177 Cr export revenue). Unproven at scale

  • "Formulation sales showing momentum"

  • Reality: ₹111 Cr in Q2 vs ₹72 Cr in Q1 — genuine Q-o-Q growth, but from weak base

Where the profit disappeared

The ₹72.3% collapse in net profit traces to three causes. First, domestic demand withered: monsoon deficiency and erratic rainfall disrupted paddy, kharif, and horticulture planting across Maharashtra, Andhra Pradesh, Karnataka, Punjab, and Haryana. Herbicide application weakened sharply; Q2 revenue fell 59.6% YoY. Second, margins compressed: EBITDA margin fell 380 bps to 14.4% (from 18.2% prior year) due to higher employee costs, freight inflation, forex losses, and job-work charges (₹12 Cr in Q2, up from ₹6 Cr in Q2 FY26). Backward integration (75% complete) has not yet offset cost inflation. Third, capex drag is front-loaded: ₹65 Cr capitalized to Hamirpur in September; infrastructure is in place but capacity ramp is behind prior guidance.

Domestic revenue stress

Implied ₹50–70 Cr Q2

weak herbicide application, monsoon

EBITDA margin compression

-380 bps YoY

18.2% → 14.4%; wages, freight, forex

Job-work charge jump

₹12 Cr Q2

vs ₹6 Cr Q2 FY26; masks underlying margin pressure

The bull-bear ledger

One side of the trade
  • Export orders (₹100 Cr) now materializing; Europe & Australia market entry

  • Regulatory approvals (UK, Argentina) provide new market optionality; 8 products in pipeline

  • Formulation scaling (₹111 Cr Q2) — higher margin business; capex not yet absorbed

  • Intermediate backward integration (75% complete) — Pretilachlor now in-house

  • Operating cash flow healthy: ₹48 Cr H1; net cash position ₹36 Cr vs ₹29 Cr March

The other side
  • Domestic demand collapse (-59.6% revenue YoY) with no near-term recovery visible

  • Margin compression unresolved; OPM 13.4% below stated targets; backward integration benefits delayed

  • Hamirpur capex (₹120–135 Cr total) front-loaded; returns speculative; subsidiary unproven

  • Guidance credibility weak: revenue halved, margin targets cut 160–360 bps in 2 quarters

  • Export orders unproven at scale; geopolitical risk and supply-chain volatility cited as portfolio drivers

Ranked risks: what should concern a holder

Risk severity and why it matters

Domestic demand remains structurally weak

High

Monsoon deficiency persists into H2 FY27. Revenue guidance already defensive (maintenance, not growth). Herbicide demand may not snap back; cumulative -59.6% YoY is not a cyclical blip.

Margin recovery contingent on multiple moving parts

High

EBITDA margin 14.4% vs. 15–18% target. Backward integration benefits delayed. Freight/forex headwinds persist. Formulation scaling and capex absorption critical to margin recovery; no guarantee.

Hamirpur capex execution and subsidiary losses

High

₹120–135 Cr capex total, ₹65 Cr already capitalized. Only 2 of 10 blocks operational. Subsidiary expected ₹40–50 Cr H2 revenue (unproven); possible losses until scale achieved. Capital-heavy bet with uncertain ROI.

Export order book concentration and fulfillment risk

Medium

₹100 Cr orders from unnamed Europe/Australia customers. Execution depends on supply-chain stability and geopolitical conditions. If major customer defaults or supply disrupts, order book at risk.

Regulatory approval ramp-up uncertain

Medium

Argentina ₹20–25 Cr Y1 target is conservative. UK expansion needs to prove at customer pull. 8 products in pipeline (Australia, Brazil, Canada, Asia) carry approval and market-entry risk.

Guidance credibility collapse

Medium

Management has cut revenue guidance, margin targets, and Hamirpur ramp twice in two quarters. Next miss triggers rating downgrade and further FII outflow.

How the market is reading it

The stock's price action tells the story. IPL trades at ₹117.15, down 72.87% from its all-time high of ₹431.75, and sits below all major moving averages (SMA20 ₹119.13, SMA50 ₹128.19, SMA200 ₹147.61). The stock is 7.22% above its 52-week low of ₹109.26—technical weakness, not recovery. More damning: FII ownership has collapsed to 0.20% in Q1 FY27 from 1.87% in Q4 FY26—a 1.67 percentage-point exodus in a single quarter. Promoter ownership remains stable at 63.65%, but the institutional vote of confidence has fled.

Bulk dealing activity in mid-September (around ₹144) showed mixed flows—brokers cycling positions—but no sustained institutional demand. The combination of margin compression, guidance downgrades, and FII exit suggests the market views IPL as a story in distress, not recovery. The 73% drawdown from ATH is not noise; it reflects real structural problems.

The honest debate

What to watch next (Q3 and beyond)

Catalysts that could reset the debate
  • 1 · Export order execution begins (Q3 onwards)

    ₹100 Cr in hand. Q3 should show material export revenue uptick if execution is real. Track: export revenue trajectory in Q3 vs. ₹88–89 Cr run-rate seen in H1 and partial execution in Q2.

  • 2 · Hamirpur blocks 3–4 operational, subsidiary revenue ramp

    Management guided ₹40–50 Cr H2 subsidiary revenue. Q3 results will confirm if 2 new blocks are online and revenue is materializing. This is the capex returns test.

  • 3 · Domestic demand stabilization

    Post-monsoon planting patterns will show in Q3–Q4. If herbicide application accelerates and domestic revenue grows Q-o-Q, the structural weakness narrative breaks. If it remains flat/negative, the downside case hardens.

  • 4 · Margin trajectory

    The single number to track: OPM. If it stays below 14%, backward-integration story is unconvincing. If it moves toward 15–16%, the margin-recovery narrative is alive. Watch also: job-work charges in Q3 (should trend lower as Hamirpur capacity absorbs conversion in-house).

India Pesticides is not having a bad quarter. It is having the quarter of a company in structural transition, and the transition is not working as promised. Revenue collapsed, margins compressed below targets, and management has reset guidance lower twice in two quarters. Export orders and new approvals are genuine, but immaterial at current scale. Capex is front-loaded and returns are lagging. The FII exodus (0.20% ownership, down from 1.87%) is a vote of no-confidence.

The stock's 73% drawdown from ATH is not an opportunity to buy the dip. It is the market correctly pricing in the execution risk and credibility loss. Until domestic demand stabilizes, capex delivers revenue at promised margins, and management restores credibility through execution, the burden of proof is on the company, not the bear case.

Verdict: Hold. The number to track: OPM in Q3–Q4. If it stays below 14%, the margin-recovery story is dead and further downside likely. If it moves to 15–16%, the story resets.

Informational and educational content only. Not investment advice.